Comparative study on uric acid lowering effects of different regimens on pyrazinamide induced hyperuricemia
SU Lingling1 ZHENG Meiqin2 XU Rui2 LIU Qiuyue3 GUO Zhenyong2 LIU Shuo2
1.Department of General, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; 2.Department of Pharmacy, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; 3.Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
Abstract：Objective To compare the effect of different intervention schemes on lowering uric acid in pyrazinamide induced hyperuricemia. Methods The adverse reaction reports of pyrazinamide induced hyperuricemia in Beijing Chest Hospital Affiliated to Capital Medical University from January 2012 to December 2022 were searched. The basic information and blood uric acid level of the patients were collected, and the patients were divided into benbromarone treatment group (74 cases), lifestyle intervention group (31 cases), pyrazinamide disuse group (25 cases) and allopurinol treatment group (4 cases) according to the way of lowering uric acid. Using the change rate of blood uric acid level as index, the effect of lowering uric acid in each group was compared by one-way ANOVA. Results A total of 134 patients were included, including 91 males (67.9%). The median age was 30 (22, 51) years; body weight (58.8±11.8) kg; height (169.1±7.4) cm; 107 cases (79.9%) were treated with first-line anti-tuberculosis therapy. Days of application of pyrazinamide 7 (6, 9) days; there were 22 patients (16.4%) with history of drug allergy. There were significant differences in blood uric acid at 3 to 5 weeks after the intervention and the change rate of uric acid after the intervention (P＜0.05). Among them, the change rate of blood uric acid in benbromarone treatment group, lifestyle intervention group and allopurinol treatment group at 3 to 5 weeks after intervention was higher than that of pyrazinamide disuse group, and the change rate of uric acid in lifestyle intervention group was higher than that of benbromarone treatment group, with statistical significances (P＜0.05). Conclusion Among the four programs to reduce blood uric acid, the withdrawal of pyrazinamide is the most effective, and the use of benzbromarone can also reduce uric acid, but the effect of lifestyle intervention is not as good as the above two programs.
[1] Enomoto A，Kimura H，Chairoungdua A，et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels [J]. Nature，2002，417（6887）：447-452. [2] Ichida K，Hosoyamada M，Kimura H，et al. Urate transport via human PAH transporter hOAT1 and its gene structure [J]. Kidney Int，2003，63（1）：143-155. [3] 田娜妮，何青青，朱琳，等.吡嗪酰胺相关高尿酸血症的影响因素分析[J].中国医药导刊，2022，24（4）：389-392. [4] 蒲强红，李佳萌，李凡敏，等.结核病化疗药物吡嗪酰胺致高尿酸血症的危险因素研究[J].中华全科医学，2021， 19（12）：2058-2060，2152. [5] 杨江华，王伟.吡嗪酰胺化疗对肺结核患者血尿酸水平的影响及苯溴马隆的干预治疗[J].安徽医药，2016（2）：384-385，386. [6] 郑火珺.吡嗪酰胺致高尿酸血症临床调查分析[J].中国药业，2013，22（8）：88-89. [7] 陈明，吴珂，吴首蓉，等.结核患者血清尿酸与吡嗪酰胺血药浓度关系研究[J].中国药物应用与监测，2018，15（5）：274-276. [8] Taki H，Ogawa K，Murakami T，et al. Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide [J]. Kekkaku，2008，83（7）：497- 501. [9] 雷艳萍，雷金艳，雷飞燕.抗结核药吡嗪酰胺引起继发性痛风的临床观察[J].中国现代医生，2010，48（10）：131-132. [10] 杜小娟，夏淑东.吡嗪酰胺致尿酸升高及痛风的临床观察[J].临床合理用药杂志，2011，4（14）：57. [11] 徐东，朱小霞，曾学军，等.痛风诊疗规范[J].中华内科杂志，2020，59（6）：421-426. [12] Kodama S，Saito K，Yachi Y，et al. Association between serum uric acid and development of type 2 diabetes [J]. Diabetes Care，2009，32（9）：1737-1742. [13] Kim SY，Guevara JP，Kim KM，et al. Hyperuricemia and coronary heart disease：a systematic review and meta-analysis [J]. Arthritis Care Res （Hoboken），2010，62（2）：170- 180. [14] Xia X，Luo Q，Li B，et al. Serum uric acid and mortality in chronic kidney disease：A systematic review and meta-analysis [J]. Metabolism，2016，65（9）：1326-1341. [15] Pichholiya M，Yadav AK，Luhadia SK，et al. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients [J]. Indian J Pharmacol，2016，48（5）：522-525. [16] 陈薇，顾颖，戚之燕，等.饮食干预对继发型结核患者抗结核治疗后高尿酸血症的影响[J].海军医学杂志，2014， 35（3）：223-224. [17] 申恩瑞，彭惠，陈青，等.停用吡嗪酰胺对初治结核病患者血尿酸水平的影响[J].广东医学，2018，39（24）：3701- 3705. [18] 国家食品药品监督管理局药品安全监管司，国家药品不良反应监测中心编.药品不良反应报告和监测工作手册[S].2012：49. [19] Moriwaki Y，Yamamoto T，Takahashi S，et al. Analysis of uric acid transport in renal tubules using benzbromarone and pyrazinamide [J]. Int J Clin Pharmacol Ther Toxicol，1990， 28（2）：84-88. [20] Han XQ，Pang Y，Ma Y，et al. Prevalence and risk factors associated with adverse drug reactions among previously treated tuberculosis patients in China [J]. Biomed Environ Sci，2017，30（2）：139-142. [21] 郑兰，汪洁，钟辉，等.吡嗪酰胺抗结核治疗前后血尿酸水平变化的相关性研究[J].临床合理用药杂志，2012，5（8）：1-3. [22] ■i■manlar T，Aslan AT，Budako■lu I. Is Hyperuricemia Over- looked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? [J]. J Trop Pediatr，2015，61（5）：351-356. [23] 袁进，梁虹艺，石磊.吡嗪酰胺抗结核化疗致高尿酸血症流行病学调查[J].药物流行病学杂志，2012，21（2）：78-80. [24] 刘硕，康万里，许瑞，等.吡嗪酰胺相关高尿酸血症患者血尿酸升高程度的影响因素分析[J].药物不良反应杂志，2020，22（12）：665-669. [25] 高尿酸血症相关疾病诊疗多学科共识专家组.中国高尿酸血症相关疾病诊疗多学科专家共识[J].中华内科杂志，2017，56（3）：235-248. [26] Reinders MK，van Roon EN，Houtman PM，et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients [J]. Clin Rheumatol，2007，26（9）：1459-1465. [27] Chou HW，Chiu HT，Tsai CW，et al. Comparative effectiveness of allopurinol，febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia：a 13-year inception cohort study [J]. Nephrol Dial Transplant，2018，33（9）：1620-1627.
2023, Vol. 20 
京公网安备 11010502046598号